MedTrace Logo

SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

NCT06804161 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2025-12-22

No results posted yet for this study

Summary

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.

Conditions

  • Atrial Hypertension

Interventions

DRUG

SGLT2

10 mg

DRUG

Placebo

1 tablet

Sponsors & Collaborators

  • Prof. Dr. med. Ingo Eitel

    lead OTHER

Principal Investigators

  • Ingo Eitel, Prof. Dr. · Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-10
Primary Completion
2032-05-30
Completion
2032-05-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06804161 on ClinicalTrials.gov